Advances in Study on Role of Butyrate in Prevention and Treatment of Non-alcoholic Fatty Liver Disease
10.3969/j.issn.1008-7125.2020.01.010
- Author:
Mengqing LI
1
Author Information
1. Department of Gastroenterology, Affiliated Hospital of Jiangsu University
- Publication Type:Journal Article
- Keywords:
Butyrates;
Inflammation;
Intestinal Mucosal Barrier;
Lipid Metabolisms;
Mitochondria;
Non-Alcoholic Fatty Liver Disease;
Therapy
- From:
Chinese Journal of Gastroenterology
2020;25(1):47-50
- CountryChina
- Language:Chinese
-
Abstract:
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, and its incidence is increasing year by year. The mechanism of NAFLD is not fully understood, and it lacks effective prevention and treatment. Recent studies have found that butyrate, as a short-chain fatty acids (SCFAs), plays an important role in gene regulation, immunoregulation, inhibition of tumor, regulation of intestinal mucosal barrier, and reduction of oxidative stress. Several studies have shown that butyrate could alleviate NAFLD. This article reviewed the mechanism of butyrate in the pathogenesis of NAFLD and its application in the treatment of NAFLD, so as to provide a new idea for the prevention and treatment of NAFLD.
